A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
| Status: | Completed |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 20 - Any |
| Updated: | 3/22/2017 |
| Start Date: | September 30, 2015 |
| End Date: | March 3, 2017 |
Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease
This two-part study will evaluate how safe LY3154207 is and the effects it has on the body.
Part A will include healthy participants. Each participant will receive daily doses of
LY3154207 or placebo for 14 days. Part A will last approximately 4 weeks including a 17 day
stay in the clinical research unit (CRU) and follow-up.
Part B is contingent on the results of Part A. Part B will include participants with
Parkinson's disease. Each participant will receive daily doses of LY3154207 or placebo for
14 days. Part B will last approximately 4 weeks including a 17 day stay in the CRU and
follow-up.
Both Part A and Part B will require screening within 30 days prior to the start of the
study.
Part A will include healthy participants. Each participant will receive daily doses of
LY3154207 or placebo for 14 days. Part A will last approximately 4 weeks including a 17 day
stay in the clinical research unit (CRU) and follow-up.
Part B is contingent on the results of Part A. Part B will include participants with
Parkinson's disease. Each participant will receive daily doses of LY3154207 or placebo for
14 days. Part B will last approximately 4 weeks including a 17 day stay in the CRU and
follow-up.
Both Part A and Part B will require screening within 30 days prior to the start of the
study.
Inclusion Criteria:
Part A:
- Overtly healthy males or females, as determined by medical history and physical
examination
- Female participants not of child-bearing potential
Part B:
- Have a clinical diagnosis of idiopathic Parkinson's disease for at least 1 year and
on stable medication for at least 4 weeks
Part A and B
- Are reliable and willing to make themselves available for the duration of the study
and are willing to follow study procedures
- Have given written informed consent
- Have a body mass index (BMI) of 18.0 to 29.9 kilograms per square meter (kg/m²)
Exclusion Criteria:
- Have participated, in the last 30 days, in a clinical trial involving an
investigational product
- Have a significant history of or current cardiovascular, respiratory, hepatic, renal,
gastrointestinal, endocrine, hematological or neurological disorders capable of
significantly altering the absorption, metabolism or elimination of drugs; or
constituting a risk when taking the study medication; or interfering with the
interpretation of study data
We found this trial at
3
sites
Glendale, California 91206
Principal Investigator: H. Gevorkyan, MD
Phone: 818-254-1600
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials